Navigation Links
VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings
Date:10/20/2009

SARATOGA, Calif., Oct. 20 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for individuals with age-related macular degeneration (AMD), today announced upcoming scientific and corporate presentations on its implantable telescope technology. VisionCare's investigational telescope implant is the first medical device to be recommended for FDA approval by the FDA Ophthalmic Devices Advisory Panel for End-Stage AMD, a leading cause of untreatable blindness in the U.S.

    Three podium presentations are scheduled as follows:

    American Academy of Ophthalmology (AAO) Annual Meeting
    October 23 - 27, 2009 - Moscone Center, San Francisco.

        -  Friday, October 23
           Session: AAO Retina 2009 Subspecialty Day, Late Breaking
           Developments
           Location: Moscone Center South, Esplanade Ballroom

           3:28 PM Long-term Data on the Implantable Telescope Technology
           Jeffrey S. Heier, MD, Vitreoretinal Specialist, Ophthalmic
           Consultants of Boston, Boston, MA.

        -  Monday, October 26
           Session: AAO Joint Meeting, Symposium 25
           Location: Moscone Center South, Esplanade Ballroom

           5:14 PM Implantable Miniaturized Telescope
           Mark R. Wilkins, MD, Cornea/Cataract Specialist, Moorfields Eye
           Hospital, London.

    Ophthalmology Innovation Summit (OIS)
    October 22, 2009 - The Palace Hotel, San Francisco.

        -  8:50 AM VisionCare Ophthalmic Technologies
           Allen W. Hill, President and CEO

At the AAO annual meeting, VisionCare is in Booth #5437 located in the West Hall of the Moscone Convention Center.

About the Telescope Device

The investigational Implantable Miniature Telescope (by Dr. Isaac Lipshitz) is designed to be a solution for moderate to profound vision loss due to advanced, end-stage forms of AMD that have no current surgical or medical treatment options. Smaller than a pea, the telescope prosthetic device is implanted in one eye in an outpatient surgical procedure. In the implanted eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision, while the non-operated eye provides peripheral vision for mobility and orientation. On March 27, the FDA Ophthalmic Devices Advisory Panel unanimously recommended that the FDA approve, with conditions, the premarket application (PMA) for VisionCare's device for End-Stage AMD. The telescope implant is the first medical device to be recommended by the panel for FDA approval for End-Stage AMD, a leading cause of untreatable blindness in the U.S. The company anticipates FDA approval within the next few months. The device has received CE Mark approval in Europe.

About Macular Degeneration

Macular degeneration is a disorder of the central retina, or macula, which is responsible for detailed vision that controls important functional visual activities like recognizing faces and watching television. According to the National Eye Institute over 1.7 million Americans over age 50 suffer mild to profound vision loss from advanced AMD, which frequently culminates as End-Stage AMD (visual impairment due to untreatable advanced AMD). Patients affected in both eyes often experience a loss of independence, social interaction, and have difficulty with activities of daily living requiring detailed vision. Approximately half of the individuals living with advanced AMD are affected in both eyes.

About VisionCare

VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA is a privately-held company focused on development, manufacturing, and marketing of visual prosthetic devices. The Implantable Miniature Telescope was invented by company founders, Yossi Gross and Isaac Lipshitz. Information on VisionCare can be found at www.visioncareinc.net.

SOURCE VisionCare Ophthalmic Technologies, Inc.


'/>"/>
SOURCE VisionCare Ophthalmic Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
2. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
3. Implantable Defibrillators Lower Risk of Death in Older Heart Patients
4. Can Implantable Devices for Heart Failure Help Assess Risk of Future Adverse Events for Heart Failure Patients?
5. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
6. Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500(TM)
7. e-Zassi.com Provides Industry With Online U.S. FDA Regulatory Calculator for Rapid Medical Device Technology Assessment
8. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
9. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
10. ECRI Institute Sees Upward Trend in Hospital Medical Technology Evaluation Activity
11. Verathon Introduces the GlideScope(R) Cobalt Advanced Video Laryngoscope (AVL); New Digital Technology Facilitates Quick Intubations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... a major "team investment" by Bruce Montgomery , one of this area,s most prominent biotech ... Leen Kawas , PhD. Photo - ... ... ... Kawas said the round was intended to be an $8 ...
(Date:2/11/2016)... , Feb. 11, 2016  AcelRx Pharmaceuticals, Inc. ... presentation will be made at the 38th annual ... Wound Care Symposium, which is being held February 14-18, ... conference covers the latest advancements in wound healing, burn ... American Burn Association, Australian-New Zealand Burns Association, Academy of ...
(Date:2/11/2016)... TEL AVIV, Israel , Feb. 11, 2016  Galmed ... clinical-stage biopharmaceutical company focused on the development of a ... announced today that its Chief Medical Officer, Dr. ... retiring from Galmed as Chief Medical Officer and from ... 2016 due to her reaching retirement age. ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified ... series of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve ... The series, known as “Mindfulness for Actors and Artists,” has been featured in ...
(Date:2/10/2016)... , ... February 10, 2016 , ... LaserShip, a regional ... to the Food Bank of Eastern Michigan last Friday in order to aid in ... into the Midwest to include a facility located in Clio, only 15 miles away ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... to expand dental health services to the developmentally disabled in the Coachella Valley. ... operations to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho ...
(Date:2/10/2016)... ... 10, 2016 , ... As part of its ongoing series of aquatic therapy ... webinar features a dynamic expert and thoughtful presentation to give attendees a better sense ... Both events are free to attend, but registration is required. , Rehabilitation ...
(Date:2/10/2016)... ... 10, 2016 , ... Intermedix announced on Wednesday that it ... emergency medicine professional association, to support the organization's newly established physician group with ... Emergency Medicine, or AAEM, seeks to empower emergency physicians to control their own ...
Breaking Medicine News(10 mins):